Mindpeak Breast
Overview
Mindpeak Breast (part of the Mindpeak Breast Suite) is an AI-powered digital pathology software designed to assist pathologists in analyzing and scoring immunohistochemistry (IHC) breast cancer biomarkers. The tool automates the detection, classification, and quantification of key breast cancer receptors, specifically targeting HER2, Ki-67, ER (Estrogen Receptor), and PR (Progesterone Receptor).
Developed for clinical laboratories, hospitals, and digital pathology practices, the tool integrates directly into existing workflows. It is compatible with major Whole Slide Image (WSI) scanners and is accessible through leading digital pathology platforms and Laboratory Information Systems (LIS), such as Paige, Sectra, and ZayaAI.
Notable Capabilities:
- Automated IHC Quantification: Automatically detects and classifies tumor cells within whole slide images, distinguishing between stained (positive) and unstained (negative) cells to generate precise proliferation and expression scores.
- HER2 Scoring: Classifies membrane staining intensity (0, 1+, 2+, 3+) in accordance with ASCO/CAP guidelines, supporting the identification of HER2-low and HER2-ultralow cases.
- Ki-67 Proliferation Indexing: Offers automated hotspot and global scoring methods (such as the Ki-67 HS and Ki-67 4R protocols) to evaluate tumor proliferation.
- Out-of-the-Box Adaptability: Designed to work with real-world image variability across different staining systems and scanners without requiring manual, lab-specific fine-tuning.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered image analysis for breast pathology
- Standardized interpretation of biomarker analysis
- Reduced inter-observer variability in diagnostics
- Automated tissue analysis for faster results
- Detection and classification of IHC stained tumor cells
- Quantification of HER2, Ki-67, ER, PR, and p53 expression in breast cancer
- Automated tissue segmentation and tumor detection on H&E slides
- 0-click AI solutions for automated image analysis
- Integration with existing lab workflows, scanners, LIS, and cloud storage
- Support for drug development, patient stratification, and clinical trials
Use Cases
- Primary breast cancer diagnosis
- Automated assessment of breast cancer biomarkers (HER2, Ki-67, ER, PR, p53)
- Streamlining pathology workflows and improving efficiency
- Supporting macro-dissection workflows
- Biomarker discovery and development for pharmaceutical companies
- Prognostic risk profiling of breast cancer
Details
| Category | Oncology AI, Pathology AI |
| Pricing | Not disclosed — Contact for pricing information |
| Deployment | On-premise (without cloud connectivity for data privacy and security), integrated into partner platforms (e.g., Paige Platform, Sectra PACS, PathAI's AISight Dx IMS) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Unknown AI-estimated Mindpeak's AI algorithms were among the first to be deployed for routine clinical diagnostics in both the US and EU. However, specific FDA clearance for 'Mindpeak Breast' as a singular product is not explicitly stated in the search results, though some individual breast cancer modules are CE-IVD marked. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Pathology, Radiology |
What the Web Says
Mindpeak Breast offers AI-powered solutions designed to assist pathologists in the detection and quantification of breast cancer cells and metastases from digital histopathology images. The software aims to improve diagnostic efficiency, accuracy, and consistency by automating tedious tasks and enhancing interobserver agreement. It has received CE-IVD mark and is being integrated into various digital pathology workflows in Europe and the US.
Overall: PositiveStrengths
- Increases diagnostic efficiency and reduces manual analysis time for pathologists.
- Enhances diagnostic accuracy and improves interobserver agreement among pathologists.
- Provides reliable quantification of key biomarkers like HER2, Ki-67, ER, and PR.
- Demonstrated high accuracy in comparative studies, outperforming other commercial AI solutions for HER2-low scoring.
- Seamlessly integrates with leading digital pathology platforms, offering a complete workflow experience.
- Reduces reporting time significantly, in some cases by 80% or more.
Limitations
- Pricing details are not readily available and require direct vendor contact.
- Limited public reviews available on platforms like G2 and Capterra, making it difficult to gauge widespread user sentiment from those sources.
- While AI assists, human judgment and review remain essential to eliminate false positives.
- Some alternatives are highly rated for customer support and customization, which are not explicitly highlighted for Mindpeak Breast in the provided information.
- Potential for a learning curve with any new system, although onboarding staff are generally knowledgeable for similar systems.
Based on reviews from: Real Reviews, Cypath, PMC (PubMed Central), Business Wire, Mindpeak, G2, Tissuepathology.com, BioSpace, Mynewsdesk, Paige, Capterra, YouTube (WION)
Last updated: 2026-07-11
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Mindpeak Breast
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Mindpeak Breast.
BREAKING NEWS: Partnership to Deploy AI in Cancer Diagnostics- Episode 30 on Digital Pathology Today
Digital Pathology Today
New AI Tool Boosts Accuracy in HER2-Low and HER2-Ultralow Breast Cancer Scoring
Breast Cancers Today
ZayaAI 2025 Digital Pathology LIMS
Zaya AI
Ready to dive into the world ud83cudf10 of A.I. and Deep Learning in Pathology?
Dr. Aleks Digital Pathology & AI
178: Live from London: Essential Digital Pathology & AI Insights 2025
Dr. Aleks Digital Pathology & AI
Dr. Khalid Daifalla Welcome Note for 5th Emirates #PathologyConference December 1-3, 2020 #CMEMeet
Utilitarian Conferences Gathering Limited
